Granted Patent
B2
US 12,678,422 · App. 17/862,117 · Granted Jul 14, 2026
Sulcardine salts
Inventors:
Suzanne J. Romano (Carlsbad, CA); Hayley Ann Reece (Dalkeith, GB); Joseph Edward Gordon Benson (Edinburgh, GB); Sarah Collins (Edinburgh, GB); Gary T. Elliott (San Diego, CA); Mireille Gillings (San Diego, CA); Robert Goodenow (San Diego, CA); Curtis Tyree (San Diego, CA)
Assignee:
HUYABIO International, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
Claims (12)
1 . A solid form, comprising a crystalline hydrochloric acid salt of sulcardine characterized by an XRPD pattern comprising peaks at approximately 12.3, 13.0, and 17.8° 2θ.
2 . The solid form of claim 1 , wherein the XRPD pattern further comprises peaks at approximately 13.9, 17.4, and 23.9° 2θ.
3 . The solid form of claim 2 , wherein the XRPD pattern further comprises peaks at approximately 20.3 and 21.9° 2θ.
4 . The solid form of claim 1 , characterized by an XRPD pattern that matches the XRPD pattern presented in FIG. 17 .
5 . A solid form, comprising a crystalline hydrochloric acid salt of sulcardine characterized by an XRPD pattern comprising peaks at approximately 13.5, 19.6, and 20.6° 2θ.
6 . The solid form of claim 5 , wherein the XRPD pattern further comprises peaks at approximately 10.1, 11.8, and 16.4° 2θ.
7 . The solid form of claim 6 , wherein the XRPD pattern further comprises peaks at approximately 17.8, 19.4, and 25.5° 2θ.
8 . The solid form of claim 5 , characterized by an XRPD pattern that matches the XRPD pattern presented in FIG. 17 A .
9 . A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a solid form, comprising a crystalline hydrochloric acid salt of sulcardine characterized by an XRPD pattern comprising peaks at approximately 12.3, 13.0, and 17.8° 2θ.
10 . The pharmaceutical composition of claim 9 , further comprising a capsule.
11 . A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and solid form, comprising a crystalline hydrochloric acid salt of sulcardine characterized by an XRPD pattern comprising peaks at approximately 13.5, 19.6, and 20.6° 2θ.
12 . The pharmaceutical composition of claim 11 , further comprising a capsule.
Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 6, 2025
From: ROMANO, SUZANNE J.; ELLIOTT, GARY T.; GILLINGS, MIREILLE; GOODENOW, ROBERT; TYREE, CURTIS
To: HUYA BIOSCIENCE INTERNATIONAL, LLC
Reel/Frame 069757/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 6, 2025
From: HUYA BIOSCIENCE INTERNATIONAL, LLC
To: HUYABIO INTERNATIONAL, LLC
Reel/Frame 069827/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 6, 2025
From: REECE, HALYLEY ANN; BENSON, JOSEPH EDWARD GORDON; COLLINS, SARAH
To: SOLID FORM SOLUTIONS, LTD.
Reel/Frame 070581/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 6, 2025
From: SOLID FORM SOLUTIONS, LTD.
To: HUYA BIOSCIENCE INTERNATIONAL, LLC
Reel/Frame 070581/0496 →
SECURITY INTEREST
Recorded Feb 21, 2024
From: HUYABIO INTERNATIONAL, LLC
To: R-BRIDGE INVESTMENT SIX PTE. LTD.
Reel/Frame 066515/0036 →
Continuity (5)
Provisional Application
62959687
· Jan 10, 2020
Provisional Application
62798467
· Jan 29, 2019
Related Publication
20250144072A9
· May 8, 2025
References Cited (66)
US 6605635B1
· Donglu et al.
· 2003
[cited by applicant]
US 8541464B2
· Elliott
· 2013
[cited by applicant]
US 8637566B2
· Elliott
· 2014
[cited by applicant]
CN 1299813C
· 2007
[cited by applicant]
CN 1939298A
· 2007
[cited by applicant]
WO 0142204A1
· 2001
[cited by applicant]
WO 2011062903A2
· 2011
[cited by applicant]
WO 2011062906A2
· 2011
[cited by applicant]
WO WO2011062903
· 2011
[cited by examiner]
WO 2018137686A1
· 2018
[cited by applicant]
WO 2020123824A1
· 2020
[cited by applicant]
Berge et al. J. Pharm. Sci., 1977, 66 (1), 1-19.
[cited by examiner]
Bai et al., Discovery of N-(3,5-bis(1-pyrrolidylmethyl)-4-hydroxybenzyl)-4-methoxybenzenesulfamide (sulcardine) as a novel anti-arrhythmic agent. Acta Pharmacologica Sinica 33(9):1176-1186 (2012).
[cited by applicant]
Chen et al., Characteristics of hERG and hNav1.5 channel blockade by sulcardine sulfate, a novel anti-arrhythmic compound. European Journal of Pharmacology 844:130-138 (2019).
[cited by applicant]
Lu et al., Oral bioavailability and mass balance studies of a novel anti-arrhythmic agent sulcardine sulfate in Sprague- Dawley rats and beagle dogs. European Journal of Drug Metabolism and Pharmacokinetics 42(3):453-45…
[cited by applicant]
PCT/US2019/066003 International Search Report and Written Opinion dated Mar. 20, 2020.
[cited by applicant]
PCT/US2020/015370 International Search Report and Written Opinion dated Jun. 6, 2020.
[cited by applicant]
PCT/US2020/015370 Invitation to Pay Additional Fees dated May 15, 2020.
[cited by applicant]
“Drugs in Japan,” Medicinal Drug Collection, Jiho Takeda, 27th Edition, 2004, p. 2631, p. 2386.
[cited by applicant]
“Guidance of Industry- Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,” U.S. Department of Health and Human Services, Pharmacology and Toxicology, Jul. …
[cited by applicant]
Anonymous, A Phase 1, randomised, double-blind, placebo-controlled, serial cohort dose- escalation study of intravenously administered HBI-3000. Clinicaltrials.gov study# NCT03397641 (2018).
[cited by applicant]
Anonymous, Abstracts from the 2009 Annual Meeting of the International Society for Heart Research North American Section: New Discoveries for Prevention and Treatment of Heart Disease. Baltimore, MD, United States. May …
[cited by applicant]
Anonymous, HUYA Bioscience Int'l Announces First Pre-Ind Outcome For A Development Stage Compound Sourced From China - Hbi-8000, Promising New Cancer Compound. [Press release] “https://www.huyabio.com/huya-bioscience-in…
[cited by applicant]
Chen et al., Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects. Fundamental & Clinical Pharmacology 31(1):120-125 (2017).
[cited by applicant]
Chinese Office Action for CN201080051906, mailed Jun. 23, 2014 (4 pages, English Translation).
[cited by applicant]
Chinese Office Action for CN2014104749461, mailed Dec. 30, 2015 (5 pages, English Translation).
[cited by applicant]
Chinese Office Action for CN201510364466, mailed Aug. 9, 2017 (7 pages, English Translation).
[cited by applicant]
Chinese Search Report for CN2010800519066, mailed Jun. 13, 2014, (1 Page).
[cited by applicant]
Chinese search report for CN2010800519070, mailed Aug. 6, 2013 (1 page).
[cited by applicant]
Chinese search report for CN2014104749461, mailed Dec. 17, 2015 (1 page).
[cited by applicant]
Chinese search report for CN201510364466, mailed Jul. 20, 2017 (2 pages).
[cited by applicant]
Chinese search report for CN2020800047961, mailed Aug. 19, 2021 (1 pages).
[cited by applicant]
David C. Lee and Michael L. Webb, Pharmaceutical Analysis, Wiley- Blackwell, Feb. 2009, pp. 255-257.
[cited by applicant]
European Supplementary Search Report for EP10832056 mailed Apr. 22, 2013 (5 pages).
[cited by applicant]
European Supplementary Search Report for EP10832058 mailed May 14, 2013 (5 pages).
[cited by applicant]
European Supplementary Search Report for EP17182709 mailed Mar. 22, 2018 (6 pages).
[cited by applicant]
Guo et al., Electrophysiologic effect of HBI-3000: A novel antiarrhythmic compound with multiple channels blocking characteristics in human atrial and ventricular myocytes. Journal of Molecular and Cellular Cardiology 4…
[cited by applicant]
Guo et al., Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. Journal of Cardiovascular Pharmacology 57(1):79-85 (2011).
[cited by applicant]
Japanese Decision of Refusal for JP2012-539070, drafted Apr. 2, 2015, (4 pages with English Translation).
[cited by applicant]
Japanese Decision of Refusal for JP2012-539071, drafted Apr. 22, 2015, (5 pages with English Translation).
[cited by applicant]
Japanese Notice of Reasons of Refusal for JP2015-157843, drafted May 27, 2016 (4 pages, English Translation).
[cited by applicant]
Japanese Notice of Reasons of Refusal for JP2015-171604, drafted Jul. 22, 2016 (2 pages, English Translation).
[cited by applicant]
Japanese Notice of Reasons of Refusal for JP2015-171604, drafted Nov. 14, 2016 (3 pages, English Translation).
[cited by applicant]
Jia et al., Determination of the novel antiarrhythmic drug sulcardine sulfate in human plasma by liquid chromatography tandem mass spectrometry and its application in a clinical pharmacokinetic study. Biomedical Chromat…
[cited by applicant]
LaPointe, et al., “Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: A case series.” American Heart Journal 139.1, Jan. 2000, pp. 114-121.
[cited by applicant]
LEE at al., HBI-3000 prevents secondary sudden cardiac death. Journal of Cardiovascular Pharmacology and Therapeutics 18(5): 453-459 (2013).
[cited by applicant]
Lee et al., Antifibrillatory actions of HBI-3000 in the conscious canine model of sudden cardiac death. The FASEB Journal 23(SI): LB376 [Abstract XP009168686] (2009).
[cited by applicant]
Lee et al., HBI-3000 prevents sudden cardiac death in a conscious canine model. Cardiac Electrophysiology Society, CES Annual Meeting. Chicago, IL, United States. Nov. 2, 13010-Nov. 13, 2010; Heart Rhythm 7(11):1712 (20…
[cited by applicant]
Mason, et al. “HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation-Phase | Study Results.” HUYA Bioscience International, Circulation 140, Suppl, 1, 2019, Page All495.
[cited by applicant]
PCT/US2021/37098 International Search Report and Written Opinion dated Oct. 6, 2021 (3 pages).
[cited by applicant]
Qi et al., Innovative drug R&D in China. Nature Reviews Drug Discovery 10(5):333- 334 (2011).
[cited by applicant]
Singh, et al., “N-Acylated sulfonamide sodium salt: A prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol- 1-yl) benzenesulfonamide class of COX-2 inhibitors,” Bioorganic & Medic…
[cited by applicant]
Streitwiesser et al., “Introduction to Organic Chemistry”, Macmillan Publishing Co., 1992, p. 736.
[cited by applicant]
Wang, et al., “Electrophysiological Characterization of a Novel Artiarrhythmic Agent - Sulcardine Salts,” Aact A Pharmacologica Sinica, Jul. 2006. Vol. 27, Suppl. 1, p. 123.
[cited by applicant]
Wang et al., Multiple dose pharmacokinetics and safety of sulcardine sulfate in healthy Chinese male subjects: an open-label phase I clinical study. European Journal of Drug Metabolism and Pharmacokinetics 42(4):593-599…
[cited by applicant]
Wang, et al., “Effect of Sulcardine on cardiac electrophysiology in anesthetized rabbits,” Chinese Pharmacological Society Communication vol. 19, No. 4, Nov. 4, 2002, pp. 63-64.
[cited by applicant]
U.S. Appl. No. 16/712,677 Office Action dated Apr. 12, 2021.
[cited by applicant]
U.S. Appl. No. 16/775,142, filed Jan. 28, 2020.
[cited by applicant]